{
    "organizations": [],
    "uuid": "2b5edaefc6d6723895ed1cec12a2764b9e156e74",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-and-european-medicines-agen/brief-u-s-fda-and-european-medicines-agency-accept-regulatory-submissions-for-review-of-dacomitinib-idUSASC09UV4",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA And European Medicines Agency Accept Regulatory Submissions For Review Of Dacomitinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Pfizer Inc:\n* ACTIVATING MUTATIONS * ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR A DECISION BY FDA IS IN SEPTEMBER 2018​\n* ‍EUROPEAN MEDICINES AGENCY HAS ALSO ACCEPTED MARKETING AUTHORIZATION APPLICATION FOR DACOMITINIB FOR SAME INDICATION​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-04-04T20:02:00.000+03:00",
    "crawled": "2018-04-05T17:23:49.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "pfizer",
        "inc",
        "activating",
        "mutation",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "goal",
        "date",
        "decision",
        "fda",
        "september",
        "medicine",
        "agency",
        "also",
        "accepted",
        "marketing",
        "authorization",
        "application",
        "dacomitinib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}